A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

(2011) D. M. Benson et al.   BLOOD

Update on risk stratification and treatment of newly diagnosed multiple myeloma

(2011) Prashant Kapoor et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

(2010) A. K. Hsu et al.   BLOOD

Natural killer cell activity in monoclonal gammopathies: Relation to disease activity

(2010) A. Österborg et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Effects of induction with novel agentsversusconventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma

(2010) Don M. Benson et al.   LEUKEMIA & LYMPHOMA

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

(2009) F. Romagne et al.   BLOOD

Human natural killer cells

(2008) M. A. Caligiuri   BLOOD

Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

(2008) Dan Zhu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH